Search Results

Now showing 1 - 1 of 1

Add to my favorites
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
(SAGE Publications, 2018) Rodríguez-Abreu, D. (Delvys); Gonzalez-Cao, M. (María); Perez-Ruiz, E. (Elisabeth); Martin-Algarra, S. (Salvador); Llanos-Gil, M. (Maria) de los; Marquez-Rodas, I. (Iván); Royo, M.A. (María Ángeles); Teixidó, C. (Cristina); Puertolas, T. (Teresa); Drozdowskyj, A. (Ana); Rosell, R. (Rafael); Gimenez-Capitan, A. (Ana); Blanco, R. (Remedios); Karachaliou, N. (Niki); Viteri, S. (S.); Crespo, G. (Guillermo); Aldeguer, E. (Erika); Molina-Vila, M.A. (Miguel Angel)
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-y). We have explored whether the expression of IFNG, the gene encoding IFN-y, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined.